Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268393
Max Phase: Preclinical
Molecular Formula: C61H45Cl6N7O15
Molecular Weight: 1328.78
Associated Items:
ID: ALA5268393
Max Phase: Preclinical
Molecular Formula: C61H45Cl6N7O15
Molecular Weight: 1328.78
Associated Items:
Canonical SMILES: CN1C(=O)[C@@H](c2cc(Cl)c(O)c(Cl)c2)NC(=O)[C@@H]2NC(=O)[C@@H](c3cc(Cl)c(O)c(Cl)c3)NC(=O)[C@H](NC(=O)C(=O)c3cc(Cl)c(O)c(Cl)c3)Cc3cc4ccc(cc4[nH]3)-c3cc2cc(c3O)Oc2ccc(cc2)C[C@H]1C(=O)N[C@@H](C(=O)O)c1ccc(O)cc1
Standard InChI: InChI=1S/C61H45Cl6N7O15/c1-74-44(56(82)73-49(61(87)88)25-6-8-33(75)9-7-25)12-24-2-10-34(11-3-24)89-45-22-28-14-35(51(45)77)26-4-5-27-13-32(68-42(27)21-26)23-43(69-59(85)50(76)31-19-40(66)54(80)41(67)20-31)55(81)70-47(29-15-36(62)52(78)37(63)16-29)57(83)71-46(28)58(84)72-48(60(74)86)30-17-38(64)53(79)39(65)18-30/h2-11,13-22,43-44,46-49,68,75,77-80H,12,23H2,1H3,(H,69,85)(H,70,81)(H,71,83)(H,72,84)(H,73,82)(H,87,88)/t43-,44+,46-,47-,48-,49-/m1/s1
Standard InChI Key: XOIMFBLBDPZGLR-OTLJHNKQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1328.78 | Molecular Weight (Monoisotopic): 1325.1105 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Rana P, Ghouse SM, Akunuri R, Madhavi YV, Chopra S, Nanduri S.. (2020) FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors., 208 [PMID:32883635] [10.1016/j.ejmech.2020.112757] |
Source(1):